Integrated Filing — IndAS


General information about company

Scrip Code 532296
NSE Symbol GLENMARK
MSEI Symbol NOTLISTED
ISIN INE935A01035
Name of company Glenmark Pharmaceuticals Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 23-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 12-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 23-May-2025   14:00:00
End date and time of board meeting 23-May-2025   16:54:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-14
Indicate Company website link for updated RPT policy of the Company https://glenmark.b-cdn.net/gpl_pdfs/about_us/Policy%20on%20RPT%20and%20its%20Materiality.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The Company is debt free.



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 20094930000 92264090000
Other income 884520000 3563660000
Total income 20979450000 95827750000
2 Expenses
(a) Cost of materials consumed 6960130000 27814470000
(b) Purchases of stock-in-trade 914820000 3732070000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -13780000 444760000
(d) Employee benefit expense 3827030000 16034980000
(e) Finance costs 131270000 487330000
(f) Depreciation, depletion and amortisation expense 555290000 2186290000
(f) Other Expenses
1 Other Expenses 5001480000 21796010000
Total other expenses 5001480000 21796010000
Total expenses 17376240000 72495910000
3 Total profit before exceptional items and tax 3603210000 23331840000
4 Exceptional items -1791660000 -1791660000
5 Total profit before tax 1811550000 21540180000
6 Tax expense
7 Current tax -256210000 3160870000
8 Deferred tax 590160000 2275810000
9 Total tax expenses 333950000 5436680000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 1477600000 16103500000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 1477600000 16103500000
17 Other comprehensive income net of taxes -30010000 -64660000
18 Total Comprehensive Income for the period 1447590000 16038840000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 282190000 282190000
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve 244757370000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 5.24 57.07
Diluted earnings (loss) per share from continuing operations 5.24 57.07
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.24 57.07
Diluted earnings (loss) per share from continuing and discontinued operations 5.24 57.07
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 16608090000
Capital work-in-progress 1213380000
Investment property 1244170000
Goodwill 0
Other intangible assets 1939500000
Intangible assets under development 332210000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 151949070000
Trade receivables, non-current 0
Loans, non-current 57542540000
Other non-current financial assets 456880000
Total non-current financial assets 209948490000
Deferred tax assets (net) 0
Other non-current assets 1270230000
Total non-current assets 232556070000
2 Current assets
Inventories 13693110000
Current financial asset
Current investments 0
Trade receivables, current 25501560000
Cash and cash equivalents 1314510000
Bank balance other than cash and cash equivalents 12910000
Loans, current 0
Other current financial assets 189870000
Total current financial assets 27018850000
Current tax assets (net) 0
Other current assets 7064780000
Total current assets 47776740000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 280332810000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 282190000
Other equity 244757370000
Total equity attributable to owners of parent 245039560000
Non controlling interest
Total equity 245039560000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 2251550000
Total non-current financial liabilities 2251550000
Provisions, non-current 0
Deferred tax liabilities (net) 582610000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 2834160000
Current liabilities
Current financial liabilities
Borrowings, current 6988200000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 214410000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 21012170000
Total Trade payable 21226580000
Other current financial liabilities 2015610000
Total current financial liabilities 30230390000
Other current liabilities 970790000
Provisions, current 1257910000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 32459090000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 35293250000
Total equity and liabilites 280332810000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss -46130000 -99390000
Total Amount of items that will not be reclassified to profit and loss -46130000 -99390000
2 Income tax relating to items that will not be reclassified to profit or loss -16120000 -34730000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -30010000 -64660000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 21540180000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 487330000
Adjustments for decrease (increase) in inventories -2266250000
Adjustments for decrease (increase) in trade receivables, current -290600000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 1990800000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -10799400000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 2186290000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 332880000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -1180550000
Adjustments for dividend income 60000
Adjustments for interest income 2051760000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 270000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -24060000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 1791660000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -9823450000
Net cash flows from (used in) operations 11716730000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 5828760000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 5887970000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 13650000
Purchase of property, plant and equipment 3409540000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 7450300000
Purchase of other long-term assets 117500000
Cash advances and loans made to other parties 10866200000
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 24470000
Dividends received 60000
Interest received 2010250000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -660000
Net cash flows from (used in) investing activities -4895170000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 592220000
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 399890000
Dividends paid 704420000
Interest paid 442020000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -954110000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 38690000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents -3820000
Net increase (decrease) in cash and cash equivalents 34870000
Cash and cash equivalents cash flow statement at beginning of period 1279640000
Cash and cash equivalents cash flow statement at end of period 1314510000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Suresh Surana & Associates LLP Yes 31-Mar-2028


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 1180000 0 0
2 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Sale of goods or services - 15610000 0 0
3 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 1990000 0 0
4 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 970000 0 0
5 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Sale of goods or services - 25530000 0 0
6 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals sro. CZ Wholly Owned Subsidiary Purchase of goods or services - 8310000 0 0
7 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals sro. CZ Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 8650000 0 0
8 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals sro. CZ Wholly Owned Subsidiary Sale of goods or services - 442090000 0 0
9 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals sro. CZ Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 2530000 0 0
10 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals sro. CZ Wholly Owned Subsidiary Purchase of goods or services - 1035770000 0 0
11 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 180000 0 0
12 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Purchase of goods or services - 184100000 0 0
13 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Sale of goods or services - 378600000 0 0
14 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Sale of goods or services - 7290000 0 0
15 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 16350000 0 0
16 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Purchase of goods or services - 268670000 0 0
17 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 610000 0 0
18 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Sale of goods or services - 341110000 0 0
19 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 840000 0 0
20 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Sale of goods or services - 680000 0 0
21 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Purchase of goods or services - 100370000 0 0
22 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Any other transaction Purchase of fixed assets - 114300000 0 0
23 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 50580000 0 0
24 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Sale of goods or services - 1394420000 0 0
25 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Sale of goods or services - 44240000 0 0
26 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 50840000 0 0
27 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U. Wholly Owned Subsidiary Sale of goods or services - 246210000 0 0
28 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidiary Sale of goods or services - 2100000 0 0
29 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U. Wholly Owned Subsidiary Sale of goods or services - 50000 0 0
30 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U. Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 9320000 0 0
31 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Purchase of goods or services - 6110000 0 0
32 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Sale of goods or services - 470860000 0 0
33 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Sale of goods or services - 50000 0 0
34 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 4640000 0 0
35 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidiary Sale of goods or services - 1077390000 0 0
36 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidiary Sale of goods or services - 310000 0 0
37 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 30660000 0 0
38 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidiary Sale of goods or services - 79980000 0 0
39 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Compensation payment in accordance with agreement - 8130000 0 0
40 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 2880000 0 0
41 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Purchase of fixed assets - 12890000 0 0
42 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 221230000 0 0
43 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Sale of goods or services - 1142530000 0 0
44 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Sale of goods or services - 560000 0 0
45 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Sale of goods or services - 3710000 0 0
46 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Sale of goods or services - 590000 0 0
47 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Any other transaction Expenses paid on behalf of others - 740000 0 0
48 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Any other transaction Compensation payment in accordance with agreement - 69230000 0 0
49 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 16380000 0 0
50 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Purchase of goods or services - 17950000 0 0
51 Glenmark Pharmaceuticals Europe Ltd, UK Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 3060000 0 0
52 Glenmark Arzneimittel GmbH, Germany Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Sale of goods or services - 24080000 0 0
53 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 330000 0 0
54 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 8730000 0 0
55 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Purchase of goods or services - 20790000 0 0
56 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 840000 0 0
57 Glenmark Pharmaceuticals Europe Ltd, UK Viso Farmaceutica S.L.U. Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 250000 0 0
58 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 1530000 0 0
59 Glenmark Pharmaceuticals Europe Ltd, UK Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Interest on Loan - 3120000 0 0
60 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Interest on Loan - 68960000 0 0
61 Glenmark Pharmaceuticals Kenya Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd Wholly Owned Subsidiary Purchase of goods or services - 1230000 0 0
62 Glenmark Pharmaceuticals Kenya Limited Glenmark Generics S.A. Wholly Owned Subsidiary Purchase of goods or services - 4450000 0 0
63 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Generics S.A. Wholly Owned Subsidiary Purchase of goods or services - 22820000 0 0
64 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Farmaceuticals Ltda Brazil Wholly Owned Subsidiary Purchase of goods or services - 11370000 0 0
65 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd. -Peru Wholly Owned Subsidiary Sale of goods or services - 7340000 0 0
66 Glenmark Farmaceuticals Ltda Brazil Glenmark Ecuador Wholly Owned Subsidiary Sale of goods or services - 3730000 0 0
67 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly Owned Subsidiary Any other transaction Reimbursement (Cross Charge) - 11050000 0 0
68 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd.-Chile Wholly Owned Subsidiary Any other transaction Reimbursement (Cross Charge) - 1340000 0 0
69 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly Owned Subsidiary Purchase of goods or services - 140730000 0 0
70 Glenmark Ecuador Glenmark Pharmaceuticals Ltd. -Peru Wholly Owned Subsidiary Sale of goods or services - 5210000 0 0
71 Glenmark Ecuador Glenmark Generics S.A. Wholly Owned Subsidiary Purchase of goods or services - 30000 0 0
72 Glenmark Generics S.A Argentina Glenmark Pharmaceuticals Colombia Wholly Owned Subsidiary Sale of goods or services - 10000 0 0
73 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 1880000 0 0
74 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark Impex Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 180000 0 0
75 Glenmark Pharmaceuticals Europe Ltd, UK Glenmark impex Wholly Owned Subsidiary Any other transaction Reimbursement Charges Received - 180000 0 0
76 Glenmark Pharmaceuticals Europe Ltd, UK Viso Farmaceutica S.L.U. Wholly Owned Subsidiary Any other transaction Reimbursement Charges Paid - 2260000 0 0
77 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Any other transaction Payable - 0 460000 0
78 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Any other transaction Receivable - 0 19430000 16860000
79 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Payable - 0 100000 890000
80 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Receivable - 0 17610000 4350000
81 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Ukraine LLC Wholly Owned Subsidiary Any other transaction Receivable - 0 10000 10000
82 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals sro. CZ Wholly Owned Subsidiary Any other transaction Payable - 0 278160000 73060000
83 Glenmark Pharmaceuticals Distribution s.r.o. Glenmark Pharmaceuticals sro. CZ Wholly Owned Subsidiary Any other transaction Receivable - 0 374710000 209030000
84 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Any other transaction Payable - 0 156930000 40990000
85 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SK SRO, Slovak Republic Wholly Owned Subsidiary Any other transaction Receivable - 0 659500000 432960000
86 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Payable - 0 138280000 127530000
87 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Receivable - 0 665380000 508130000
88 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd, UK Wholly Owned Subsidiary Any other transaction Payable - 0 27720000 152760000
89 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals Europe Ltd, UK Wholly Owned Subsidiary Any other transaction Receivable - 0 451130000 499170000
90 Glenmark Pharmaceuticals s.r.o. Viso Farmaceutica S.L.U., Spain Wholly Owned Subsidiary Any other transaction Receivable - 0 262330000 155810000
91 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Any other transaction Payable - 0 4860000 3020000
92 Glenmark Pharmaceuticals s.r.o. Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Any other transaction Receivable - 0 119060000 172500000
93 Glenmark Pharmaceuticals s.r.o. Glenmark Nordics SE Wholly Owned Subsidiary Any other transaction Receivable - 0 995440000 1341920000
94 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Payable - 0 37420000 152040000
95 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Receivable - 0 302030000 460040000
96 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Any other transaction Receivable - 0 330000 14830000
97 Glenmark Pharmaceuticals s.r.o. Glenmark Generics S.A. Wholly Owned Subsidiary Any other transaction Receivable - 0 2320000 2300000
98 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Receivable - 0 45510000 102020000
99 Glenmark Pharmaceuticals s.r.o. Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Any other transaction Payable - 0 0 71150000
100 Glenmark Pharmaceuticals s.r.o. Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Payable - 0 0 8360000
101 Glenmark Pharmaceuticals Europe Limited Viso Farmaceutica S.L.U., Spain Wholly Owned Subsidiary Any other transaction Receivable - 0 13180000 2110000
102 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals BV Wholly Owned Subsidiary Any other transaction Payable - 0 11820000 32510000
103 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals SP Zoo, Poland Wholly Owned Subsidiary Any other transaction Payable - 0 290000 0
104 Glenmark Pharmaceuticals Europe Limited Glenmark Nordics SE Wholly Owned Subsidiary Any other transaction Receivable - 0 2600000 4120000
105 Glenmark Pharmaceuticals Europe Limited Glenmark Impex Wholly Owned Subsidiary Any other transaction Receivable - 0 510000 690000
106 Glenmark Pharmaceuticals Europe Limited Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Receivable - 0 5660000 5960000
107 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Payable - 0 69520000 9620000
108 Glenmark Pharmaceuticals Europe Limited Glenmark Generics S.A. Wholly Owned Subsidiary Any other transaction Receivable - 0 590000 580000
109 Glenmark Pharmaceuticals Europe Limited Glenmark Pharmaceuticals Mexico SA de CV Wholly Owned Subsidiary Any other transaction Receivable - 0 260000 250000
110 Glenmark Pharmaceuticals Europe Limited Glenmark Farmaceutica Ltda., Brazil Wholly Owned Subsidiary Any other transaction Receivable - 0 3720000 3850000
111 Glenmark Pharmaceuticals Europe Limited Sintesy Pharma S.r.l. Wholly Owned Subsidiary Any other transaction Loan given - 0 115750000 114380000
112 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH, Germany Wholly Owned Subsidiary Any other transaction Loan given - 0 2899520000 2821930000
113 Glenmark Pharmaceuticals Europe Limited Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Any other transaction Receivable - 0 0 330000
114 Glenmark Arzneimittel GmbH, Germany Glenmark Arzneimittel GmbH (Austria) Wholly Owned Subsidiary Any other transaction Receivable - 0 0 24080000
115 Glenmark Pharmaceuticals Kenya Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd Wholly Owned Subsidiary Any other transaction Payable - 0 3930000 1260000
116 Glenmark Pharmaceuticals Kenya Limited Glenmark Generics S.A. Wholly Owned Subsidiary Any other transaction Payable - 0 0 0
117 Glenmark Pharmaceuticals Kenya Limited Glenmark Egypt Wholly Owned Subsidiary Any other transaction Receivable - 0 2050000 2100000
118 Glenmark Pharmaceuticals South Africa (Pty) Ltd Glenmark South Africa (Pty) Ltd Wholly Owned Subsidiary Any other transaction Loan Given - 0 460220000 440370000
119 Glenmark Pharmaceuticals South Africa (Pty) Ltd Glenmark South Africa (Pty) Ltd Wholly Owned Subsidiary Investment - 0 25900000 25900000
120 Glenmark Pharmaceuticals Mexico SA de CV Glenmark Generics S.A. Wholly Owned Subsidiary Any other transaction Payable - 0 5190000 0
121 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Mexico SA de CV Wholly Owned Subsidiary Any other transaction Receivable - 0 10740000 16370000
122 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd. Peru Wholly Owned Subsidiary Any other transaction Payable - 0 5290000 5370000
123 Glenmark Farmaceuticals Ltda Brazil Glenmark Pharmaceuticals Ltd. Peru Wholly Owned Subsidiary Any other transaction Payable - 0 100000 0
124 Glenmark Farmaceuticals Ltda Brazil Glenmark Ecuador Wholly Owned Subsidiary Any other transaction Receivable - 0 1170000 2540000
125 Glenmark Farmaceuticals Ltda Brazil Glenmark Generics S.A. Wholly Owned Subsidiary Any other transaction Payable - 0 73780000 24370000
126 Glenmark Pharmaceuticals Venezuela Glenmark Generics S.A. Wholly Owned Subsidiary Any other transaction Payable - 0 14120000 17000000
127 Glenmark Pharmaceuticals Ltd. -Peru Glenmark Ecuador Wholly Owned Subsidiary Any other transaction Payable - 0 0 2610000
128 Glenmark Generics S.A. Glenmark Ecuador Wholly Owned Subsidiary Any other transaction Receivable - 0 3260000 0
129 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidiary Investment - 0 15186690000 15186690000
130 Glenmark Holding S.A. Glenmark Pharmaceuticals s.r.o. Wholly Owned Subsidiary Investment - 0 7194780000 7194780000
131 Glenmark Holding S.A. Glenmark Distributors s.r.o. Wholly Owned Subsidiary Investment - 0 1646120000 1646120000
132 Glenmark Holding S.A. Glenmark Pharmaceuticals Sp.z.o.o, Warsaw, Poland Wholly Owned Subsidiary Investment - 0 367830000 367830000
133 Glenmark Holding S.A. Glenmark Arzneimitel GmbH, Germany Wholly Owned Subsidiary Investment - 0 106840000 106840000
134 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly Owned Subsidiary Investment - 0 1480000 1480000
135 Glenmark Holding S.A. Viso Farmaceutica SL, Madrid, Spain Wholly Owned Subsidiary Investment - 0 210000 210000
136 Glenmark Holding S.A. Glenmark Ukraine, Wholly Owned Subsidiary Investment - 0 46150000 46150000
137 Glenmark Holding S.A. Glenmark Pharmaceuticals Nordic AB Wholly Owned Subsidiary Investment - 0 173930000 173930000
138 Glenmark Holding S.A. Glenmark Farmacêutica Ltda Wholly Owned Subsidiary Investment - 0 15639210000 15670520000
139 Glenmark Holding S.A. Glenmark Farmacêutica Ltda Wholly Owned Subsidiary Investment - 31300000 0 0
140 Glenmark Holding S.A. Glenmark Generics SA Wholly Owned Subsidiary Investment - 0 10183670000 10553710000
141 Glenmark Holding S.A. Glenmark Generics SA Wholly Owned Subsidiary Investment - 370040000 0 0
142 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly Owned Subsidiary Investment - 0 38363540000 38363540000
143 Glenmark Holding S.A. Glenmark Therapeutics Inc. Wholly Owned Subsidiary Investment - 0 2481700000 2481700000
144 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc Canada Wholly Owned Subsidiary Investment - 0 107570000 107570000
145 Glenmark Holding S.A. Sintesy Pharma S.R.L Wholly Owned Subsidiary Investment - 0 155950000 155950000
146 Glenmark Holding S.A. Ichnos Sciences Inc Wholly Owned Subsidiary Investment - 0 38022830000 40888690000
147 Glenmark Holding S.A. Ichnos Sciences Inc Wholly Owned Subsidiary Investment - 2865900000 0 0
148 Glenmark Holding S.A. Glenmark Arzneimittel GmBH, Austria Wholly Owned Subsidiary Investment - 0 51680000 52250000
149 Glenmark Holding S.A. Glenmark Arzneimittel GmBH, Austria Wholly Owned Subsidiary Investment - 600000 0 0
150 Glenmark Holding S.A. Glenmark Farmaceutica Spa., Chile Wholly Owned Subsidiary Investment - 0 12400000 12400000
151 Glenmark Specialty S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidiary Any other transaction Payable - 0 6240000 47990000
152 Glenmark Specialty S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidiary Any other transaction Expense - 43100000 0 0
153 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidiary Any other transaction Payable - 0 40200000 177500000
154 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidiary Any other transaction Expense - 137100000 0 0
155 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly Owned Subsidiary Any other transaction Payable - 0 900000 25500000
156 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly Owned Subsidiary Any other transaction Expense - 24700000 0 0
157 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly Owned Subsidiary Any other transaction Payable - 0 0 1800000
158 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly Owned Subsidiary Any other transaction Expense - 1800000 0 0
159 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidiary Any other transaction Receivable - 0 5925600000 7664800000
160 Glenmark Specialty S.A. Glenmark Pharmaceuticals Inc. USA Wholly Owned Subsidiary Sale of goods or services - 1588600000 0 0
161 Glenmark Specialty S.A. Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly Owned Subsidiary Any other transaction Receivable - 0 184600000 385800000
162 Glenmark Specialty S.A. Glenmark Pharmaceuticals South Africa (Pty) Ltd. Wholly Owned Subsidiary Sale of goods or services - 217200000 0 0
163 Glenmark Specialty S.A. Glenmark Impex LLC Wholly Owned Subsidiary Any other transaction Receivable - 0 286800000 508200000
164 Glenmark Specialty S.A. Glenmark Impex LLC Wholly Owned Subsidiary Sale of goods or services - 214810000 0 0
165 Glenmark Specialty S.A. Glenmark Pharmaceuticals Peru S.A Wholly Owned Subsidiary Any other transaction Receivable - 0 7440000 29810000
166 Glenmark Specialty S.A. Glenmark Pharmaceuticals Peru S.A Wholly Owned Subsidiary Sale of goods or services - 29920000 0 0
167 Glenmark Specialty S.A. Glenmark Pharmaceuticals Ecuador S.A. Wholly Owned Subsidiary Any other transaction Receivable - 0 6980000 39250000
168 Glenmark Specialty S.A. Glenmark Pharmaceuticals Ecuador S.A. Wholly Owned Subsidiary Sale of goods or services - 31890000 0 0
169 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly Owned Subsidiary Any other transaction Receivable - 0 1294340000 1717500000
170 Glenmark Specialty S.A. Glenmark Pharmaceuticals S.R.O. Wholly Owned Subsidiary Sale of goods or services - 1691320000 0 0
171 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly Owned Subsidiary Any other transaction Receivable - 0 7480000 25870000
172 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS KENYA LTD. Wholly Owned Subsidiary Sale of goods or services - 18070000 0 0
173 Glenmark Specialty S.A. Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly Owned Subsidiary Any other transaction Receivable - 0 0 28210000
174 Glenmark Specialty S.A. Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly Owned Subsidiary Sale of goods or services - 44590000 0 0
175 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly Owned Subsidiary Any other transaction Receivable - 0 0 113880000
176 Glenmark Specialty S.A. GLENMARK PHARMACEUTICALS MEXICO SA Wholly Owned Subsidiary Sale of goods or services - 112180000 0 0
177 Glenmark Specialty S.A. Glenmark Pharmaceuticals FZE Wholly Owned Subsidiary Any other transaction Receivable - 0 32090000 32850000
178 Glenmark Specialty S.A. Ichnos Sciences Inc Wholly Owned Subsidiary Any other transaction Receivable - 0 350000 0
179 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly Owned Subsidiary Any other transaction Receivable - 0 0 11630000
180 Glenmark Specialty S.A. Glenmark Holding S.A. Wholly Owned Subsidiary Any other transaction Other income - 12590000 0 0
181 Glenmark Specialty S.A. Glenmark Pharmaceuticals Australia Wholly Owned Subsidiary Any other transaction Receivable - 0 95010000 87970000
182 Glenmark Specialty S.A. Dynafisc S.A. - George Berthoud Other related party Any other transaction Director sitting fees - 260000 0 0
183 Glenmark Specialty S.A. Dynafisc S.A. Other related party Any other transaction Professional Fees - 1660000 0 0
184 Glenmark Specialty S.A. Brian Tempest (Hale & Tempest Co Ltd) Other related party Any other transaction Director Meeting Fees - 0 250000 0
185 Glenmark Specialty S.A. Marcel Eggler (KGG & Associés) Other related party Any other transaction Director Meeting Fees - 520000 0 130000
186 Glenmark Specialty S.A. Marcel Eggler (KGG & Associés) Other related party Any other transaction Professional Fees - 150000 0 20000
187 Glenmark Specialty S.A. Dipankar Bhattacharjee Other related party Any other transaction Director Meeting Fees - 240000 0 240000
188 Glenmark Holding S.A. Dynafisc S.A. - George Berthoud Other related party Any other transaction Director Meeting Fees - 290000 0 0
189 Glenmark Holding S.A. Dynafisc S.A. Other related party Any other transaction Professional Fees - 1620000 0 0
190 Glenmark Holding S.A. Marcel Eggler (KGG & Associés) Other related party Any other transaction Director Meeting Fees - 390000 0 130000
191 Glenmark Holding S.A. Marcel Eggler (KGG & Associés) Other related party Any other transaction Professional Fees - 380000 700000 60000
192 Glenmark Holding S.A. Brian Tempest (Hale & Tempest Co Ltd) Other related party Any other transaction Director Meeting Fees - 0 250000 0
193 Glenmark Holding S.A. Dipankar Bhattacharjee Other related party Any other transaction Director Meeting Fees - 240000 0 240000
194 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidiary Any other transaction Loan Receivable - 0 4686110000 6760100000 Loan 0.045 5 years Unsecured Business purpose
195 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidiary Interest received - 104760000 0 0
196 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidiary Any other transaction Loan Given - 3977550000 0 0
197 Glenmark Holding S.A. Glenmark Pharmaceuticals Sp Z.o.o Wholly Owned Subsidiary Any other transaction Loan Receivable - 0 195130000 128860000
198 Glenmark Holding S.A. Glenmark Pharmaceuticals Sp Z.o.o Wholly Owned Subsidiary Any other transaction Interest Income - 4790000 0 0
199 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly Owned Subsidiary Any other transaction Loan Receivable - 0 7647410000 20157310000 Loan 0.05 3 years Unsecured Business purpose
200 Glenmark Holding S.A. Glenmark Pharmaceuticals Inc. Wholly Owned Subsidiary Any other transaction Loan Given - 12301120000 0 0
201 Glenmark Holding S.A. Glenmark Farmacêutica Ltda Wholly Owned Subsidiary Any other transaction Interest Payable - 0 4320000 4400000
202 Glenmark Holding S.A. Ichnos Sciences Inc Wholly Owned Subsidiary Any other transaction Dividend Receivable - 0 9099450000 13814630000
203 Glenmark Holding S.A. Ichnos Sciences Inc Wholly Owned Subsidiary Any other transaction Dividend Receivable - 4485930000 0 0
204 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidiary Any other transaction Loan Payable - 0 2482400000 1961850000 Loan 0.0465 Upto 1 year Unsecured Business purpose
205 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidiary Any other transaction Interest expense - 64050000 0 0
206 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Ltd. Wholly Owned Subsidiary Any other transaction Loan Taken - 1930800000 0 0
207 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly Owned Subsidiary Any other transaction Loan Payable - 0 1174120000 1423540000 Loan 0.0465 Upto 1 year Unsecured Business purpose
208 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly Owned Subsidiary Any other transaction Interest Expense - 22930000 0 0
209 Glenmark Holding S.A. Glenmark Pharmaceuticals B.V. Wholly Owned Subsidiary Any other transaction Loan Taken - 259390000 0 0
210 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidiary Any other transaction Payable - 0 0 11630000
211 Glenmark Holding S.A. Glenmark Specialty S.A. Wholly Owned Subsidiary Any other transaction Expense - 12590000 0 0
212 Glenmark Holding S.A. Glenmark Arzneimitel GmbH Wholly Owned Subsidiary Any other transaction Loan Payable - 0 3094080000 4293500000
213 Glenmark Holding S.A. Glenmark Arzneimitel GmbH Wholly Owned Subsidiary Any other transaction Loan Taken - 1183200000 0 0 Loan 0.0465 Upto 1 year Unsecured Business purpose
214 Glenmark Holding S.A. Glenmark Arzneimitel GmbH Wholly Owned Subsidiary Any other transaction Interest Expense - 37430000 0 0
215 Glenmark Pharmaceuticals Limited Glenmark Farmaceutica Ltda., Brazil Wholly Owned Subsidiary Sale of goods or services - 625020000 0 0
216 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Wholly Owned Subsidiary Sale of goods or services - 39800000 0 0
217 Glenmark Pharmaceuticals Limited Glenmark Phillipines Inc., Philippines Wholly Owned Subsidiary Sale of goods or services - 369870000 0 0
218 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C., Russia Wholly Owned Subsidiary Sale of goods or services - 1144960000 0 0
219 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals South Africa (Pty) Limited Wholly Owned Subsidiary Sale of goods or services - 205990000 0 0
220 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC., Peru Wholly Owned Subsidiary Sale of goods or services - 6700000 0 0
221 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd., Thailand Wholly Owned Subsidiary Sale of goods or services - 45800000 0 0
222 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd, Kenya Wholly Owned Subsidiary Sale of goods or services - 548350000 0 0
223 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia Ltda., Colombia Wholly Owned Subsidiary Sale of goods or services - 77450000 0 0
224 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico, S.A. DE C.V., Mexico Wholly Owned Subsidiary Sale of goods or services - 658590000 0 0
225 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn Bhd., Malaysia Wholly Owned Subsidiary Sale of goods or services - 39750000 0 0
226 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc., USA Wholly Owned Subsidiary Sale of goods or services - 7068300000 0 0
227 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidiary Sale of goods or services - 171900000 0 0
228 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd Wholly Owned Subsidiary Sale of goods or services - 2146930000 0 0
229 Glenmark Pharmaceuticals Limited GLENMARK GENERICS S.A. Wholly Owned Subsidiary Sale of goods or services - 12590000 0 0
230 Glenmark Pharmaceuticals Limited GLENMARK PHARMACEUTICALS ECUADOR S. Wholly Owned Subsidiary Sale of goods or services - 53020000 0 0
231 Glenmark Pharmaceuticals Limited Glenmark Therapeutics Inc., USA Wholly Owned Subsidiary Sale of goods or services - 45490000 0 0
232 Glenmark Pharmaceuticals Limited Glenmark Ukrain LLC Wholly Owned Subsidiary Sale of goods or services - 101410000 0 0
233 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc., Canada Wholly Owned Subsidiary Sale of goods or services - 463900000 0 0
234 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidiary Sale of goods or services - 990000 0 0
235 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidiary Sale of goods or services - 2581100000 0 0
236 Glenmark Pharmaceuticals Limited Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Other operating income - 25930000 0 0
237 Glenmark Pharmaceuticals Limited Ichnos Sciences Biotherapeutics S.A Wholly Owned Subsidiary Any other transaction Other operating income - 1920000 0 0
238 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidiary Any other transaction Other operating income - 791600000 0 0
239 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc. Wholly Owned Subsidiary Any other transaction Other operating income - 38280000 0 0
240 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidiary Any other transaction Fixed Asset Sale - 50000 0 0
241 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc. Wholly Owned Subsidiary Any other transaction Fixed Asset Sale - 160000 0 0
242 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc. Wholly Owned Subsidiary Purchase of goods or services - 1517460000 0 0
243 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE. Wholly Owned Subsidiary Purchase of goods or services - 304390000 0 0
244 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Limited Wholly Owned Subsidiary Purchase of goods or services - 294870000 0 0
245 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C., Russia Wholly Owned Subsidiary Purchase of goods or services - 471620000 0 0
246 Glenmark Pharmaceuticals Limited GLENMARK PHILIPPINES INC Wholly Owned Subsidiary Purchase of goods or services - 11890000 0 0
247 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidiary Purchase of goods or services - 8610000 0 0
248 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc., Canada Wholly Owned Subsidiary Purchase of goods or services - 32050000 0 0
249 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidiary Purchase of goods or services - 23140000 0 0
250 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Limited Wholly Owned Subsidiary Purchase of goods or services - 750000 0 0
251 Glenmark Pharmaceuticals Limited Glenmark Singapore Pte Ltd Wholly Owned Subsidiary Purchase of goods or services - 44710000 0 0
252 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Australia Wholly Owned Subsidiary Purchase of goods or services - 18040000 0 0
253 Glenmark Pharmaceuticals Limited Glenmark Germany Wholly Owned Subsidiary Purchase of goods or services - 30230000 0 0
254 Glenmark Pharmaceuticals Limited Glenmark Ukraine LLC Wholly Owned Subsidiary Purchase of goods or services - 7950000 0 0
255 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidiary Purchase of goods or services - 3220000 0 0
256 Glenmark Pharmaceuticals Limited Glenmark Holding S.A Wholly Owned Subsidiary Any other transaction Loan Given - 19710290000 0 0
257 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidiary Any other transaction Loan Given - 47600000 0 0
258 Glenmark Pharmaceuticals Limited Glenmark Holding S.A. Wholly Owned Subsidiary Any other transaction Interest Income - 761110000 0 0
259 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Limited Wholly Owned Subsidiary Any other transaction Interest Income - 7730000 0 0
260 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co Ltd Wholly Owned Subsidiary Any other transaction Interest Income - 370000 0 0
261 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E. Wholly Owned Subsidiary Any other transaction Interest Income - 11360000 0 0
262 Glenmark Pharmaceuticals Limited Glenmark Healthcare Ltd Wholly Owned Subsidiary Any other transaction Interest Income - 10650000 0 0
263 Glenmark Pharmaceuticals Limited Glenmark Holding S.A. Wholly Owned Subsidiary Any other transaction Other Income - 12790000 0 0
264 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidiary Any other transaction Other Income - 690000 0 0
265 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc. Wholly Owned Subsidiary Any other transaction Other Income - 13330000 0 0
266 Glenmark Pharmaceuticals Limited Glenmark Foundation Other related party Any other transaction Contribution incurred for CSR activities 300000000 - 45790000 0 0
267 Glenmark Pharmaceuticals Limited Glenmark Aquatic Foundation Other related party Any other transaction Contribution incurred for CSR activities 100000000 - 43000000 0 0
268 Glenmark Pharmaceuticals Limited Mr. Glenn Saldanha Chairman & Managing Director Remuneration - 95250000 0 0
269 Glenmark Pharmaceuticals Limited Mrs. Cherylann Pinto Executive Director Remuneration - 41050000 0 0
270 Glenmark Pharmaceuticals Limited Mr V S Mani Executive Director & Global CFO Remuneration - 66680000 0 0
271 Glenmark Pharmaceuticals Limited Mr. Harish Kuber Company Secretary & Compliance Officer Remuneration - 3590000 0 0
272 Glenmark Pharmaceuticals Limited Mr. Rajesh Desai Independent Director Any other transaction Sitting Fees - 1000000 0 0
273 Glenmark Pharmaceuticals Limited Mrs. Saira Ramasastry Independent Director Any other transaction Sitting Fees - 800000 0 0
274 Glenmark Pharmaceuticals Limited Mrs. Vijayalakshmi Iyer Independent Director Any other transaction Sitting Fees - 800000 0 0
275 Glenmark Pharmaceuticals Limited Mrs. Blanche Saldanha Independent Director Any other transaction Sitting Fees - 200000 0 0
276 Glenmark Pharmaceuticals Limited Mr. Dipankar Bhattacharjee Independent Director Any other transaction Sitting Fees - 800000 0 0
277 Glenmark Pharmaceuticals Limited Mr. Pradeep Kumar Sinha Independent Director Any other transaction Sitting Fees - 100000 0 0
278 Glenmark Pharmaceuticals Limited Glenmark Arzneimittel GmbH Wholly Owned Subsidiary Any other transaction Payable - 0 171370000 200390000
279 Glenmark Pharmaceuticals Limited Glenmark Farmaceutica Ltda., Brazil Wholly Owned Subsidiary Any other transaction Receivable - 0 1022600000 1495460000
280 Glenmark Pharmaceuticals Limited Glenmark Philippines Inc., Philippines Wholly Owned Subsidiary Any other transaction Receivable - 0 415520000 597410000
281 Glenmark Pharmaceuticals Limited Glenmark Therapeutics Inc., USA Wholly Owned Subsidiary Any other transaction Receivable - 0 35000000 58460000
282 Glenmark Pharmaceuticals Limited Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Receivable - 0 37870000 85570000
283 Glenmark Pharmaceuticals Limited Glenmark Holding S.A., Switzerland Wholly Owned Subsidiary Any other transaction Receivable - 0 37161860000 56747910000 Loan 0.03 8 years Unsecured Business purpose
284 Glenmark Pharmaceuticals Limited Ichnos Sciences Biotherapeutics S.A Wholly Owned Subsidiary Any other transaction Receivable - 0 1880000 3830000
285 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Nigeria) Ltd., Nigeria Wholly Owned Subsidiary Any other transaction Receivable - 0 331410000 331410000
286 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Nigeria) Ltd., Nigeria Wholly Owned Subsidiary Any other transaction Loan Given - 0 115260000 115260000
287 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C., Russia Wholly Owned Subsidiary Any other transaction Receivable - 0 1318920000 1631110000
288 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals South Africa (Pty) Ltd., South Africa Wholly Owned Subsidiary Any other transaction Receivable - 0 416320000 629870000
289 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE., United Arab Emirates Wholly Owned Subsidiary Any other transaction Payable - 0 697880000 701670000
290 Glenmark Pharmaceuticals Limited Glenmark Generics SA., Argentina Wholly Owned Subsidiary Any other transaction Receivable - 0 13640000 26480000
291 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Venezuela., C.A , Venezuela Wholly Owned Subsidiary Any other transaction Receivable - 0 1558200000 1558200000
292 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn.Bhd., Malaysia Wholly Owned Subsidiary Any other transaction Receivable - 0 753190000 441350000
293 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC., Peru Wholly Owned Subsidiary Any other transaction Receivable - 0 31170000 11590000
294 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd U.K. (Glenmark Generics (Europe) Ltd., U.K.) Wholly Owned Subsidiary Any other transaction Receivable - 0 947750000 382750000
295 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Inc., USA Wholly Owned Subsidiary Any other transaction Payable - 0 6467980000 3537300000
296 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals s.r.o., Czech Republic Wholly Owned Subsidiary Any other transaction Receivable - 0 3006310000 1610110000
297 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals SK, s.r.o., Slovak Republic Wholly Owned Subsidiary Any other transaction Payable - 0 10000 10000
298 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Sp. z o.o. Wholly Owned Subsidiary Any other transaction Payable - 0 160000 160000
299 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd., Thailand Wholly Owned Subsidiary Any other transaction Receivable - 0 21210000 59360000
300 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd., Thailand Wholly Owned Subsidiary Loan - 0 16460000 17160000
301 Glenmark Pharmaceuticals Limited Glenmark Uruguay S.A., Uruguay Wholly Owned Subsidiary Any other transaction Payable - 0 833560000 849370000
302 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia Ltda., Colombia Wholly Owned Subsidiary Any other transaction Receivable - 0 124010000 203780000
303 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd; Kenya Wholly Owned Subsidiary Any other transaction Receivable - 0 1633000000 1924980000
304 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd; Kenya Wholly Owned Subsidiary Loan - 0 167560000 170900000
305 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico S.A. DE C.V. Mexico Wholly Owned Subsidiary Any other transaction Receivable - 0 528880000 716470000
306 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E., Egypt Wholly Owned Subsidiary Loan - 0 299090000 316320000
307 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Canada Inc. Wholly Owned Subsidiary Any other transaction Receivable - 0 577620000 657510000
308 Glenmark Pharmaceuticals Limited Glenmark Specialty S.A. Wholly Owned Subsidiary Any other transaction Receivable - 0 6885870000 6253450000
309 Glenmark Pharmaceuticals Limited Glenmark Ukraine LLC Wholly Owned Subsidiary Any other transaction Receivable - 0 616610000 540290000
310 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ecuador S.A. Wholly Owned Subsidiary Any other transaction Receivable - 0 195450000 252530000
311 Glenmark Pharmaceuticals Limited GLENMARK PHARMACEUTICALS SINGAPORE PTE LTD Wholly Owned Subsidiary Any other transaction Payable - 0 35840000 44960000
312 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Pty Ltd Wholly Owned Subsidiary Any other transaction Receivable - 0 23610000 45470000
313 Glenmark Pharmaceuticals Limited Glenmark Healthcare Limited Wholly Owned Subsidiary Any other transaction Loan receivable - 0 233060000 291630000 Loan 0.0874 5 Unsecured Business Purpose
314 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico S.A. Wholly Owned Subsidiary Any other transaction Share application money pending allotment - 0 91710000 91710000
315 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC. Wholly Owned Subsidiary Any other transaction Share application money pending allotment - 0 10000 10000
316 Glenmark Pharmaceuticals Limited Glenmark Impex L.L.C Wholly Owned Subsidiary Investment - 0 1435610000 1435610000
317 Glenmark Pharmaceuticals Limited Glenmark Philippines Inc. Wholly Owned Subsidiary Investment - 0 116700000 116700000
318 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Malaysia Sdn Bhd Wholly Owned Subsidiary Investment - 0 97720000 97720000
319 Glenmark Pharmaceuticals Limited Glenmark Holding S.A. Wholly Owned Subsidiary Investment - 0 143231760000 113597500000
320 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Australia) Pty Ltd Wholly Owned Subsidiary Investment - 0 101720000 101720000
321 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Egypt S.A.E. Wholly Owned Subsidiary Investment - 0 421740000 421740000
322 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals FZE Wholly Owned Subsidiary Investment - 0 12920000 12920000
323 Glenmark Pharmaceuticals Limited Glenmark Dominicana SRL Wholly Owned Subsidiary Investment - 0 230000 230000
324 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Kenya Ltd Wholly Owned Subsidiary Investment - 0 97180000 97180000
325 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Colombia SAS, Colombia Wholly Owned Subsidiary Investment - 0 577470000 577470000
326 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Peru SAC Wholly Owned Subsidiary Investment - 0 827790000 827790000
327 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Mexico, S.A. DE C.V. Wholly Owned Subsidiary Investment - 0 1695290000 1695290000
328 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Europe Ltd., U.K. Wholly Owned Subsidiary Investment - 0 578230000 578230000
329 Glenmark Pharmaceuticals Limited Glenmark South Africa (pty) Ltd Wholly Owned Subsidiary Investment - 0 1044200000 1044200000
330 Glenmark Pharmaceuticals Limited Glenmark Uruguay S.A. Wholly Owned Subsidiary Investment - 0 774530000 774530000
331 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals (Thailand) Co. Ltd Wholly Owned Subsidiary Investment - 0 3720000 3720000
332 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ecuador S.A. Wholly Owned Subsidiary Investment - 0 245490000 245490000
333 Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Singapore Pte. Ltd. Wholly Owned Subsidiary Investment - 0 32730000 32730000
334 Glenmark Pharmaceuticals Limited Glenmark Healthcare Limited Wholly Owned Subsidiary Investment - 0 90500000 90500000
335 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Loan given (Net of Return) - 2294500000 7694850000 1526690000 Loan 0.05 Long Term Unsecured Operating Expense
336 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Investment - 0 30220930000 8483360000
337 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Investment written off - 30293330000 0 0
338 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Loan converted into Equity - 8623080000 0 0
339 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Interest received - 100780000 0 0
340 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Other income - 424580000 0 0
341 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Expenses reimbursed - 150000 0 0
342 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Receivable - 0 1222450000 1672750000
343 Ichnos Sciences Inc. Ichnos Sciences Biotherapeutics SA Wholly Owned Subsidiary Investment - 0 19840000 19840000
344 Ichnos Sciences Inc. Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Payable - 0 0 30000
345 Ichnos Sciences Biotherapeutics SA Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Other income - 1850000 0 0
346 Ichnos Sciences Biotherapeutics SA Ichnos Sciences SA Wholly Owned Subsidiary Sale of goods or services - 698280000 0 0
347 Ichnos Sciences Biotherapeutics SA Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Receivable - 0 1424660000 1524650000
348 Ichnos Sciences Biotherapeutics SA Ichnos Sciences SA Wholly Owned Subsidiary Any other transaction Payable - 0 4480000 12570000
349 Glenmark Pharmaceuticals Inc. Glenmark Therapeutics Inc. Wholly Owned Subsidiary Any other transaction Loan repayment - 12720000 12720000 0 Loan 0.03 Long Term Unsecured Operating Expenses
350 Glenmark Pharmaceuticals Inc. Glenmark Therapeutics Inc. Wholly Owned Subsidiary Interest received - 250000 0 0
351 Glenmark Holding S.A. Glenmark Pharmaceuticals Europe Limited Wholly Owned Subsidiary Any other transaction Loan Repaid - 2424100000 0 0
352 Glenmark Farmaceutica Ltda Neeraj Gupta Director/KMP Remuneration - 5960000 0 0
353 Glenmark Pharmaceuticals FZE Dr Alok Chopra Director/KMP Remuneration - 18610000 0 0
354 Glenmark Pharmaceuticals FZE Csaba Kantor Director/KMP Remuneration - 44780000 0 0
355 Glenmark Pharmaceuticals Kenya Ltd Catherine Maina Director/KMP Remuneration - 1860000 0 0
356 Glenmark Generics S.A Gustavo Andrés Carrera Director/KMP Remuneration - 9600000 0 0
357 Glenmark Pharmaceuticals S.R.O. Filip Ludvik Director/KMP Remuneration - 6480000 0 0
358 Glenmark Pharmaceuticals S.R.O. Petr Podlipny Director/KMP Remuneration - 5850000 0 0
359 Glenmark Pharmaceuticals S.R.O. Andrzej Gondek Director/KMP Remuneration - 20000000 0 0
360 Glenmark Pharmaceuticals SK, S.R.O. Pavel Zachrla Director/KMP Remuneration - 10620000 0 0
361 Glenmark Pharmaceuticals Europe Ltd., U.K. Robson Tarciso de Faria Director/KMP Remuneration - 19360000 0 0
362 Glenmark Pharmaceuticals Europe Ltd., U.K. Oliver Bourne                                                      Director/KMP Remuneration - 24900000 0 0
363 Glenmark Arzneimittel GmbH Barbara Wilhelm Director/KMP Remuneration - 19210000 0 0
364 Glenmark Pharmaceuticals S.R.O. Marián Kolmokov Director/KMP Remuneration - 10660000 0 0
365 Glenmark Pharmaceuticals Nordic AB Henric Juserius Director/KMP Remuneration - 11340000 0 0
366 Glenmark Ukraine LLC Sergey Goryslavets Director/KMP Remuneration - 4020000 0 0
367 Glenmark Farmaceutica Ltda Carlos Aguiar Director/KMP Remuneration - 10400000 0 0
368 Glenmark Farmaceutica Ltda Ana Sarmento Director/KMP Remuneration - 5580000 0 0
369 Glenmark Generics S.A Victor Rodolfo Bertuccio Director/KMP Remuneration - 8860000 0 0
370 Glenmark Pharmaceuticals Mexico, S.A. DE C.V. Mariano Rozada Director/KMP Remuneration - 21720000 0 0
371 Glenmark Pharmaceuticals Mexico, S.A. DE C.V. Catalino Bocanegra Director/KMP Remuneration - 5550000 0 0
372 Glenmark Pharmaceuticals Colombia SAS, Colombia Mauricio Guerra Director/KMP Remuneration - 9410000 0 0
373 Glenmark Pharmaceuticals Inc. Sanjeev Krishan Director/KMP Remuneration - 80050000 0 0
374 Glenmark Pharmaceuticals Inc. Laura Lester Director/KMP Remuneration - 33370000 0 0
375 Glenmark Pharmaceuticals Canada Inc. Larry Mathews Director/KMP Remuneration - 25680000 0 0
376 Glenmark Pharmaceuticals B.V. Marten De jonge Director/KMP Remuneration - 13190000 0 0
377 Ichnos Sciences Inc Roberto Giovannini Director/KMP Remuneration - 33730000 0 0
Total value of transaction during the reporting period 126335980000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt